While the Outperform rating suggests that Oppenheimer's analyst believes Intellia Therapeutics will perform better than the market or sector, the reduction in the price target could imply a reassessment of the company's future growth prospects or market conditions. This news is likely to be viewed neutrally by investors as the positive rating is maintained but expectations for stock price performance are moderated.